Physician profile
Jonathan I Goldstein
NPI 1396822706
$115,242.54
in general payments reported to CMS, 2019-2025
26 companies · $67K in 2025
The $67K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $87.42 · 2021: $360 · 2022: $382 · 2023: $5,013 · 2024: $42K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $105K · Consulting Fee: $4,858 · Food and Beverage: $1,909 · Travel and Lodging: $1,821 · Education: $47.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $105,212.50 |
| Consulting Fee | $4,857.50 |
| Food and Beverage | $1,909.40 |
| Travel and Lodging | $1,820.79 |
| Education | $47.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $88,262.19 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $14,957.96 | 2019-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $6,606.55 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $3,941.82 | 2023-2025 | Rebyota, Cimzia |
| Abbvie INC. | $318.51 | 2019-2023 | |
| Pfizer INC. | $257.34 | 2019-2025 | |
| Gilead Sciences, INC. | $132.90 | 2019-2025 | |
| Celgene Corporation | $122.24 | 2019-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $92.00 | 2019-2022 | |
| Genentech USA, INC. | $90.92 | 2019 | |
| Olympus America INC. | $76.72 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $70.71 | 2022 | |
| Aimmune Therapeutics, INC. | $53.86 | 2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $51.37 | 2019-2024 | |
| Braintree Laboratories, INC. | $40.02 | 2019-2025 | Suflave, Sutab |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.71 | 2021-2022 | |
| Qol Medical, LLC | $29.27 | 2019 | |
| Intercept Pharmaceuticals, INC. | $28.16 | 2021 | |
| Ucb, INC. | $20.14 | 2019 | |
| Cook Medical LLC | $16.69 | 2023 | Caesar |
| Aries Pharmaceuticals, INC. | $15.09 | 2019 | |
| Endo Pharmaceuticals INC. | $13.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.